瀏覽海報時間

MP1-01: A real-world experience of using Apalutamide in the treatment of metastatic hormone sensitive prostate cancer

MP1-02: Public Chinese Prostate Cancer Professional Series-4：Updated Treatment for metastatic Castration-Sensitive Prostate Cancer (mCSPC) (translated from NCCN Prostate Cancer Guidelines 2023 V1)

MP1-03: Public Chinese Prostate Cancer Professional Series-5：Updated Treatment for metastatic Castration-Resistant Prostate Cancer (mCRPC) (translated from NCCN Prostate Cancer Guidelines 2023 V1)

MP1-04: Public Chinese Prostate Cancer Professional Series-1：Accurate Diagnosis of Prostate Cancer (translated from NCCN Prostate Cancer Guidelines 2023 V1)

MP1-05: Public Chinese Prostate Cancer Professional Series-3：Updated Treatment for non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) (translated from NCCN Prostate Cancer Guidelines 2023 V1)

MP1-06: Public Chinese Prostate Cancer Professional Series-2：Updated Treatment for Clinically Localized/Regional Lymph Node Invasion Prostate Cancer (translated from NCCN Prostate Cancer Guidelines 2023 V1)

MP1-07: The Impact of F18-Fluciclovine Positron Emission Tomography on Prostate Cancer Managements and Outcomes After Changing Managements

MP1-08: The long-term survival outcome of radical prostatectomy for localized prostate cancer with positive lymph node

MP1-09: Molecular Expression Differences between Epithelioid and Sporadic Renal Angiomyolipoma: The Role of PTEN Loss and mTOR Pathway Activation

MP1-10: Progression-Free Survival Following Stereotactic Body Radiotherapy for Bone Oligometastasis in Prostate Cancer and the Effect of Different Doses: A Single-Urologist, Single-Institute Experience